1. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation Xing, Yan; Lin, Nancy U.; Maurer, Matthew A.; Chen, Huiqin; Mahvash, Armeen; Sahin, Aysegul; Akcakanat, Argun; Li, Yisheng; Abramson, Vandana; Litton, Jennifer; Chavez-MacGregor, Mariana; Valero, Vicente; Piha-Paul, Sarina A.; Hong, David; Do, Kim-Anh; Tarco, Emily; Riall, Dianna; Eterovic, Agda K.; Wulf, Gerburg M.; Cantley, Lewis C.; Mills, Gordon B.; Doyle, L. A.; Winer, Eric; Hortobagyi, Gabriel N.; Gonzalez-Angulo, Ana M.; Meric-Bernstam, Funda 2019 Articles Breast--Cancer--TreatmentGenomicsBiochemical markersMutation (Biology)